Yüksel ULU, Seza Ümit TETİKKURT, Uğur İZOL, Yunus DÖNDER

Evaluation of MUC-1, MUC-4, CDX-2 and OCT-1 expression profiles in gastric carcinomas and precancerous lesions

Aim: We investigated the diagnostic and prognostic utility of MUC-1, MUC-4, CDX2 and OCT-1 expression profiles in high-mortalitygastric carcinomas and their precancerous lesions.Material and Methods: Areas in proximity of dysplasias and gastric carcinomas that were suspected of having intestinal metaplasiawere stained with PAS / Alcian Blue at pH 2.5 and pH 0.5; Giemsa staining was applied for evaluation of presence of H. Pylori.Results: Presence of MUC-1 expression may exclude the diagnosis of low-grade dysplasia. MUC-1 and MUC-4 overexpression maybe used for determination of groups at high risk of development of carcinomas, primarily in cases of high-grade dysplasia, whileoverexpression of MUC-1 in gastric carcinomas may be used as a favorable prognostic factor. Presence of CDX2 expression invarious histological types of carcinomas gives rise to a suggestion that intestinal differentiation occurs in all histological types atleast to some degree. OCT-1 plays a role in CDX2-mediated carcinogenesis and its regulation.Conclusion: In cases of dysplasia occurring with intestinal metaplasia, CDX2 was found to be expressed at a significantly higherdegree (95.5%, p=0.011). Expression of CDX2 and OCT-1 was observed in all high-grade dysplasia cases, and was significantlyhigher in comparison to low-grade dysplasia cases (p=0.042; p=0.006, respectively). MUC-1 and MUC-4 expression significantlyincreased with each progressing stage of precancerous lesions in all lesions following low-grade dysplasia (p=0.0001; p=0.027,respectively). MUC-1 expression was the lowest (53.6%) in weak cohesive type carcinomas. Positive immunoreactivity with MUC-1and CDX2 was higher in cases with a smaller number of metastatic lymph nodes compared to the cases with a larger number thereof.

PDF

___

1. Mitrut P, Burada F, Enescu A, et al. The genotoxicity study of resveratrol in primary gastric adenocarcinoma cell cultures. Rom J Morphol Embryol 2009;50:429-33.
2. Mistry M, Parkin DM, Ahmad AS, et al. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 2011;105:1795-803.
3. JooYE, Park HK, Myung DS, et al. Prevalance and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver 2013;7:303-10.
4. Chiaravalli AM, Klersy C, Vanoli A, et al. Histotypebased prognostic classification of gastric cancer. World J Gastroenterol 2012;18:538-45.
5. Akyağcı SB, Bağcıvan E, Özgüç H, ve ark. Mide Kanserinde Prognostik Faktörler. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2005;3:113-8.
6. Mutoh H, Hayakawa H, Sakamoto H, et al. Transgenic Cdx2 induces endogenous Cdx1 in istestinal metaplasia of Cdx2 – transgenic mouse stomach. FEBS J 2009:5821-31.
7. Ikarashi S, Nishikura K, Ajoika Y, et al. Re-evaluation of phenotypic expression in undifferentiated – tpye early gastric adenocarcinomas using mucin core protein and CDX2. Gastric Cancer 2013:16;208-19.
8. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
9. Bai YQ, Miyake S, Iwai T, et al. CDX2, a homeobox transcription factor, upregulates transcription of the p21/WAF1/CIP1 gene. Oncogene 2003;22:7942-9.
10. Song JH, Kim CJ, Cho YG, et al. Genetic alterations of the Cdx2 gene in gastric cancer. APMIS 2008;116:74-80.
11. Oz Puyan F, Can N, Ozyilmaz F, et al. The relationship among PDX1, CDX2 and mucin profiles in gastric carcinomas; correlations with clinicopathologic parameters. J Cancer Res Clin Oncol 2011:137;1749-62.
12. Tsukamoto T, Mizoshita T, Tatematsu M. Gastric-andintestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization. Gastric Cancer 2006:9;156-66.
13. Jin T, Li H. Pou homeodomain protein OCT1 is implicated in the expression of the caudal-related homeobox gene Cdx-2. J Biol Chem 2001:276;14752-8.
14. Almeida R, Almeida J, Shoshkes M, et al. OCT-l is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol 2005;207:396-401.
15. Carvalho F, David L, Aubert JP, et al. Mucins and mucin -associated carbonhydrate antigens expression in gastric carcinoma cell lines. Virchows Arch 1999;435:479-85.
16. Li XH, Zheng HC, Wang ZG, et al. The clinicopathological and prognostic significance of MUC1 expression in Japanese gastric carcinomas: An immunohistochemical study of tissue microarrays. Anticancer Res 2008;28:1061-7.
17. Jia Y, Persson C, Hou L, et al. A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer. Cancer Causes Control 2010;21:313-21.
18. Tamura Y, Higashi M, Kitamoto S, et al. MUC 4 and MUC1 expression in adenocarcinom of the stomach correlates with vessel invasion and lymph node metastasis: an immunohstochemical study of early gastric cancer. PloS One 2012;7:49251.
19. Senapati S, Chaturvedi P, Sharma P,et al. Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell the gastric cancer. Br J Cancer 2008;99:949-56.
20. Mejias-Luque R, Peiró S, Vincent A, et al. IL6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 2008;1783:1728-36.
21. El-Zimaity HM, Ramchatesing J, Saeed MA, et al. Gastric intestinal metaplasia : subtypes and natural history. J Clin Pathol 2001;54:679-83.
22. Sharma P, Montomery E. Gastrointestinal dysplasia. Pathology 2013;45;273-85.
23. Spiegel A, Stein P, Patel M. A Report of Fundic Gland Polyps. Gastroenterol Hepatol 2010;6:45-8.
24. Terada T. Human fetal ductal plate revisited: II. MUC 1, MUC5AC, and MUC 6 are expressed in human fetal ductal plate and MUC1 is expressed also in remodeling ductal plate, remodeled ductal plate and mature bile ducts of human fetal livers. İnt J Clin Exp Pathol 2013:6;571-85.
25. Inagaki Y, Xu H, Nakata M, et al. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastroistestinal, hepatic and pancreatic cancers. Biosci Trends 2009;3:220-32.
26. Hwang I, Kang YN, Kım JY, et al. Prognostic significance of membrane – associated mucins 1 and 4 in gastric adenocarcinoma. Exp Ther Med 2012:4;311-6.
27. Wang XT, Kong FB, Mai W,et al. MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis. Dis Markers 2016;2016:9421571.
28. İlhan Ö,Han Ü, Önal B,et al. Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma: Türk J Gastroenterology 2010;21:345-52.
29. Boltin D, Niv Y. Mucins in gastric cancer. J Gastrointest Dig Syst 2013;3:15519.
30. Tian MM, Zhao AL, Li ZW,et al. Phenotypic classification of gastric signet ring cell carcinoma and its relationship with clinicopathologic parameters and prognosis. World J Gastroenterol 2007;13:3189-98.
31. Park DY, Sirivastava A, Kim GH, et al. CDX2 expression in the intestinal type gastric epithelial neoplasia: frequency and significance. Mod Pathol 2010;23:54-61.
32. Zhang Y, Wang H ,Bi C, et al. Expression of CDX2 in gastric cardia adenocarcinoma and its correlation with H. pylori and cell proliferation. Oncotarget 2016;7:54973-82.
33. Zhao H, Jin S, Fan F, et al. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res 2000:60;6276-80.
34. Jeong SH, Lee YJ, Cho BI, et al. OCT-1 overexpression is associated with poor prognosis in patients with well-differentiated gastric cancer. Tumor Biol 2014;35:5501-9.